SAN DIEGO, November 15, 2017 – ChemDiv Inc., a fully integrated California-based CRO, announced that it has entered into a three-way co-development agreement with Context Therapeutics and Torrey Pines Investment to advance research and development in the area of Sigma1 dysfunction associated with early onset neurodegenerative diseases.

Maher, CM, Thomas, JD, Longen, CG, Oyer, HM, Kim, FJ, et al. Molecular Cancer Research.

Kim, FJ. Handbook Experimental Pharmacology.